Advanced Filters
noise

Beijing, China Clinical Trials

A listing of Beijing, China clinical trials actively recruiting patients volunteers.

Found 2,316 clinical trials
C Cui chuanliang, doctor

A Study of ST-1898 for Unresectable or Metastatic Melanoma

ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in subjects with unresectable or metastatic melanoma. In phase Ib, the primary objectives are to assess the safety and tolerability, …

18 years of age All Phase 1/2
C Cheng Cui

Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults

The aim of this study is to investigate the effects of oral D-mannose tablets for 2 consecutive weeks on the pharmacokinetics of dabigatrun etexilate, a P-glycoprotein probe substrate drug, in healthy adults

18 - 45 years of age Male Phase N/A
J Jun yang, Doctoral

Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS)

Aneurysmal subarachnoid hemorrhage (SAH) is a frequent worldwide cause for stroke with a mortality of around 30%. Worldwide, almost 500 000 patients have aneurysmal SAH annually.An incidence of 2-16 cases of spontaneous SAH per 100 000 person-years was reported in a recent meta-analysis . Surgical treatment of aneurysms is essential …

18 - 99 years of age All Phase 2/3

A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

This is a Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure

18 years of age All Phase 2/3
Y Yang Liu

Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.

18 - 90 years of age All Phase 2
N Ning Li

A Study of CSCJC3456 in Patients With Advanced Malignant Tumors

This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.

18 - 75 years of age All Phase 1
W Weili Jia

HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke

The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.

18 years of age All Phase N/A

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).

18 - 75 years of age All Phase 1
L Lin Ma

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis.

6 - 18 years of age All Phase 1/2
L Linyi Peng, MD

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and prednisone alone, so as to find new treatment measures for patients with proliferative IgG4-RD.

18 - 75 years of age All Phase 2/3

Simplify language using AI